Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Alkermes plc - Ordinary Shares (NQ:ALKS)

32.21 +0.30 (+0.94%)
Streaming Delayed Price Updated: 1:30 PM EST, Feb 23, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 916,498
Open 31.64
Bid (Size) 32.21 (300)
Ask (Size) 32.22 (200)
Prev. Close 31.91
Today's Range 31.48 - 32.23
52wk Range 25.16 - 36.32
Shares Outstanding 166,121,384
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
From Sizable Stake to Zero: The Likely Reason Why Agios Shares Lost a $94 Million Backer ↗
Agios Pharmaceuticals develops therapies for rare blood disorders, anchored by its PYRUKYND franchise and early-stage clinical programs. 
Via The Motley Fool
News headline image
Viridian Therapeutics Stock Up 75%, but One Fund Just Sold Off Its $69 Million Stake ↗
Viridian Therapeutics develops monoclonal antibody therapies targeting rare diseases, with a focus on thyroid eye disease treatments. 
Via The Motley Fool
Topics Regulatory Compliance

Performance

YTD
+14.0%
+14.0%
1 Month
-4.2%
-4.2%
3 Month
+14.2%
+14.2%
6 Month
+11.1%
+11.1%
1 Year
-9.3%
-9.3%

More News

Read More
News headline image
Spyre Therapeutics Stock Surges This Past Year as $10.5 Million Buy Lifts Stake to $78 Million ↗
Via The Motley Fool
Topics Regulatory Compliance
Race For Avadel Heats Up: Alkermes Raises Offer To Secure $2.37B Deal After Lundbeck Challenge ↗
Via Stocktwits
News headline image
Earnings Scheduled For October 28, 2025 ↗
Via Benzinga
News headline image
Preview: Alkermes's Earnings ↗
Via Benzinga
News headline image
Biotech Fund Dumps 1.85 Million Centessa Shares as Stock Jumps Over 50% ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Biotech Fund Dumps $84 Million of Nuvalent With Stock Up 29% ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Alkermes plc Completes Acquisition of Avadel Pharmaceuticals plc, Accelerating Entry Into Sleep Medicine Market
From Alkermes plc
Via Business Wire
News headline image
Alkermes to Report Fourth Quarter and Year-End Financial Results on Feb. 25, 2026
From Alkermes plc
Via Business Wire
News headline image
Alixorexton Granted Breakthrough Therapy Designation by U.S. FDA for the Treatment of Narcolepsy Type 1
From Alkermes plc
Via Business Wire
News headline image
Alkermes to Present at the 44th Annual J.P. Morgan Healthcare Conference
From Alkermes plc
Via Business Wire
News headline image
Alkermes to Participate in Two Upcoming Investor Conferences
From Alkermes plc
Via Business Wire
News headline image
Lundbeck's Higher Buyout Proposal Challenges Alkermes' Pending $2 Billion Avadel Deal ↗
Via Benzinga
News headline image
Avadel Surges 20% On Lundbeck's Surprise Alkermes-Topping Bid ↗
Via Investor's Business Daily
News headline image
Avadel Gets Acquisition Proposal From Lundbeck Weeks After Inking Agreement With Alkermes ↗
Via Stocktwits
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
Via Benzinga
News headline image
Alkermes Eyes Global Phase 3 Trial After Encouraging Data From Sleep Disorder Study ↗
Via Benzinga
News headline image
This Alkermes Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Tuesday ↗
Via Benzinga
News headline image
ALKERMES PLC (NASDAQ:ALKS) Q3 2025 Earnings Beat Estimates and Drive Stock Surge ↗
Via Chartmill
Topics Earnings
News headline image
Deal Dispatch: From Four Roses Bourbon To Quantum Stakes, Here Are This Week's Sector Shake Ups ↗
Via Benzinga
Topics Government
News headline image
Breaking Down Alkermes: 8 Analysts Share Their Views ↗
Via Benzinga
News headline image
Alkermes Strikes $2.1 Billion Avadel Deal, Gains Access To Narcolepsy Drug Lumryz ↗
Via Benzinga
News headline image
Avadel Pharmaceuticals Soars as Alkermes Announces $2.1 Billion Acquisition
Via MarketMinute
Topics Intellectual Property
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Avadel Pharmaceuticals plc (Nasdaq – AVDL), Middlefield Banc Corp. (Nasdaq – MBCN), Heidrick & Struggles International, Inc. (Nasdaq - HSII), Comerica Incorporated
From Brodsky & Smith LLC
Via GlobeNewswire

Frequently Asked Questions

Is Alkermes plc - Ordinary Shares publicly traded?
Yes, Alkermes plc - Ordinary Shares is publicly traded.
What exchange does Alkermes plc - Ordinary Shares trade on?
Alkermes plc - Ordinary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Alkermes plc - Ordinary Shares?
The ticker symbol for Alkermes plc - Ordinary Shares is ALKS on the Nasdaq Stock Market
What is the current price of Alkermes plc - Ordinary Shares?
The current price of Alkermes plc - Ordinary Shares is 32.21
When was Alkermes plc - Ordinary Shares last traded?
The last trade of Alkermes plc - Ordinary Shares was at 02/23/26 01:30 PM ET
What is the market capitalization of Alkermes plc - Ordinary Shares?
The market capitalization of Alkermes plc - Ordinary Shares is 5.35B
How many shares of Alkermes plc - Ordinary Shares are outstanding?
Alkermes plc - Ordinary Shares has 5B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.